YORVIPATH (palopegteriparatide) (Palopegteriparatide INJECTION, SOLUTION) 168 ug/.56mL

YORVIPATH (palopegteriparatide) is an FDA-approved orphan drug developed by Ascendis Pharma for the treatment of hypoparathyroidism. It is administered via subcutaneous injection and represents a novel therapeutic option in endocrinology. This medication addresses a rare metabolic disorder characterized by insufficient parathyroid hormone production.

Strength

168 ug/.56mL

Pack Size

2 BOX in 1 CARTON (73362-100-01) / 1 SYRINGE in 1 BOX (73362-100-02) / 1 CARTRIDGE in 1 SYRINGE (7

Manufacturer / TM Owner

Ascendis Pharma

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

YORVIPATH is indicated for the treatment of hypoparathyroidism, a rare endocrine disorder characterized by abnormally low levels of parathyroid hormone (PTH), resulting in hypocalcemia and hyperphosphatemia. The drug is designed for adult patients with hypoparathyroidism who require treatment to maintain calcium and phosphate homeostasis. Palopegteriparatide is a long-acting PTH analog that works by binding to PTH receptors, stimulating calcium reabsorption in the kidneys and promoting calcium mobilization from bone. This mechanism helps restore normal serum calcium levels and reduce the need for conventional therapies such as calcium supplements and active vitamin D metabolites. YORVIPATH offers patients a more physiologic approach to managing this condition, potentially improving quality of life and reducing the burden of multiple daily medications required for conventional hypoparathyroidism management.

Side Effects

Common side effects of YORVIPATH include injection site reactions, hypercalcemia, hyperphosphatemia, and headache. Serious adverse events may include severe hypercalcemia, which requires monitoring, and potential osteosarcoma risk (as with other PTH analogs). Patients require regular monitoring of serum calcium, phosphate, and magnesium levels, particularly during treatment initiation and dose adjustments. Renal function and urinary calcium should be assessed periodically. Bone turnover markers may increase, necessitating skeletal monitoring in certain patient populations.

Precautions & Warnings

YORVIPATH is contraindicated in patients with hypercalcemia or hypersensitivity to palopegteriparatide or any excipients. Caution is warranted in patients with history of skeletal malignancy, radiation therapy to the skeleton, or conditions predisposing to osteosarcoma. Use in pregnancy requires careful risk-benefit assessment; limited data exist on fetal safety. Pediatric use has not been established. Patients with severe renal impairment require dose adjustment and closer monitoring. Hepatic impairment may affect drug metabolism. Concurrent use of other PTH analogs is contraindicated.

Avoid Interactions

YORVIPATH may interact with thiazide diuretics, which increase serum calcium levels, potentially elevating hypercalcemia risk. Concurrent use of vitamin D supplements or active vitamin D metabolites requires careful monitoring and possible dose adjustment. Loop diuretics may counteract the calcium-elevating effects of palopegteriparatide. NSAIDs and other medications affecting renal function should be used cautiously. Patients should inform healthcare providers of all medications, supplements, and herbal products.

Frequently Asked Questions

YORVIPATH is used to treat hypoparathyroidism, a rare condition where the body produces insufficient parathyroid hormone. It helps restore normal calcium and phosphate levels in the blood, reducing the need for calcium supplements and vitamin D medications. YORVIPATH works by mimicking the action of natural parathyroid hormone.

YORVIPATH is administered as a subcutaneous injection, typically once weekly. Patients can self-inject after proper training by a healthcare provider. The injection is given under the skin, usually in the abdomen or thigh, and can be rotated between injection sites.

Common side effects include injection site reactions such as redness or swelling, headache, and elevated calcium levels. Most side effects are mild to moderate and tend to decrease over time. Serious side effects are rare but require immediate medical attention if they occur.

YORVIPATH is manufactured by Ascendis Pharma, a biopharmaceutical company specializing in endocrinology and rare diseases.

Yes, YORVIPATH has been designated and approved as an orphan drug by the FDA. This designation recognizes its use in treating hypoparathyroidism, a rare disease affecting a small patient population. Orphan drug status provides regulatory incentives and support for development of treatments for rare conditions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.